Indivior Plc (LON:INDV) Rating Reaffirmed
Researchers at Stifel now has a GBX 310.00 PT on Indivior Plc (LON:INDV). Stifel and their recent PT means a potential upside of 57.92% from the company’s last close price. The rating has been disclosed in a recent research report on 10 December.
From a total of 6 analysts covering Indivior Plc (LON:INDV) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 1 a ”Hold”. This means that 83% of the ratings are positive. The highest target price is GBX 4.65 while the lowest target price is GBX 3.38. The mean of all analyst targets is GBX 3.89 with a 37.74% above today’s (GBX 195.3) stock price. Indivior Plc was the topic of 19 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank maintained shares on December 10 with “Buy” rating. Citigroup upgraded shares to “Buy” rating and GBX 270 target share price in a report from a September 22. Jefferies maintained INDV stock in a recent report from November 25 with “Buy” rating. Finally, Morgan Stanley maintained the stock with “Equal-Weight” rating in a report issued on a July 24.
Approximately 223,347 shares of stock traded hands. Indivior PLC (LON:INDV) has declined 15.02% since May 13, 2015 and is downtrending. It has underperformed by 13.09% the S&P500.
Indivior PLC is a specialty pharmaceutical company. The company has a market cap of 1.40 billion GBP. The Firm and its subsidiaries are engaged in the development, manufacture, and sale of buprenorphine prescription drugs for the treatment of opioid dependence. It has 7.83 P/E ratio. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine overdose and the co-morbidity of schizophrenia.